Xcel Energy projects 7% EPS growth for 2025 with $45B capital plan
Q4 2024 Management View In 2024, Xcel Energy reported ongoing earnings of $3.50 per share, achieving its guidance range for the 20th consecutive year despite warmer-than-expected December weather. CEO ...
X4 Pharmaceuticals To Axe 30% Of Overall Workforce, Stock Falls In Pre-Market
With the strategic restructuring, X4 aims to improve operational and capital efficiency, focus on the ongoing Phase 3 clinical trial of mavorixafor in chronic neutropenia, and optimize U.S. promotion ...
X4 Pharmaceuticals announces strategic restructuring, reduces headcount by 30%
X4 Pharmaceuticals (XFOR) announced a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat ...
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM ...